Mineralys Therapeutics, Inc.(MLYS)Earnings, Financials & Key RatiosMineralys Therapeutics, Inc. (MLYS) stock price & volume — 10-year historical chart
Mineralys Therapeutics, Inc. (MLYS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Mineralys Therapeutics, Inc. (MLYS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.47vs $0.51+7.8% | — |
| Q2 2026 | Mar 12, 2026 | $0.40vs $0.52+22.5% | — |
| Q4 2025 | Nov 10, 2025 | $0.52vs $0.66+21.2% | — |
| Q3 2025 | Aug 12, 2025 | $0.66vs $0.78+15.4% | — |
Recent stock market news and headlines for Mineralys Therapeutics, Inc. (MLYS)
This clinical-stage biotech focused on hypertension therapies reported a notable insider sale amid strong one-year stock performance.
Key metrics vs top competitors for Mineralys Therapeutics, Inc. (MLYS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $30.46 | $2.02B | -13.30 | — | — | -36.91% | — | |
| $94.04 | $10.1B | 114.68 | 12.79% | 6.23% | 7.5% | — | |
| $50.77 | $69.66M | -1.00 | -100% | — | -155.4% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $74.90 | $1.46B | -7.70 | -43.89% | -284.18% | -87% | — | |
| $4.22 | $1.3B | 211.00 | 22.23% | -6.63% | — | — |
Mineralys Therapeutics, Inc. (MLYS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Mineralys Therapeutics, Inc. (MLYS) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 6, 2026·SEC
Mar 12, 2026·SEC
Mar 9, 2026·SEC
Get notified when MLYS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Mineralys Therapeutics, Inc. (MLYS) stock FAQ — growth, dividends, profitability & financials explained
Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $151.8M for fiscal year 2025.
Mineralys Therapeutics, Inc. (MLYS) has a return on equity (ROE) of -36.9%. Negative ROE indicates the company is unprofitable.
Mineralys Therapeutics, Inc. (MLYS) had negative free cash flow of $136.4M in fiscal year 2025, likely due to heavy capital investments.
